RecruitingPHASE1, PHASE2NCT04781634

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Studying Precursor B-cell acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chongqing Precision Biotech Co., Ltd
Principal Investigator
Sanbin Wang, MD, MD
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Intervention
CD19 and CD22 targeted prime CAR-T cells(biological)
Enrollment
40 enrolled
Eligibility
2-75 years · All sexes
Timeline
20212027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04781634 on ClinicalTrials.gov

Other trials for Precursor B-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Precursor B-cell acute lymphoblastic leukemia

← Back to all trials